In Canada, an estimated 7,200 people are diagnosed with melanoma every year. These cancers can affect people of all ages, but often have a pretty good prognosis, with five-year survival rate of 88 per cent. Nonetheless, an estimated 1,250 Canadians died from melanoma in 2017.
Survival often depends on when a melanoma is diagnosed, where it is located and whether it has spread, or metastasized, to other parts of the body. When cancers metastasize, they become extremely difficult to treat, and often lead to death.
Today, the lack of treatment options for patients with metastatic melanoma make melanoma a pressing health issue in Canada.
Our Research Strategy
Given these challenges, the Terry Fox Research Institute has embarked on a multi-pronged strategy to fund the best melanoma scientific teams and programs in the country.
To allocate its resources, the Institute has international experts evaluate the excellence and the potential for impact of all its research projects. This approach distinguishes our research investment strategy from all others in Canada and allows donors to be confident that their investment is supporting the top 5% of Canadian researchers and their science.